Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Katkhuda is a 5-star analyst with an average return of 30.9% and a 52.19% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Amylyx Pharmaceuticals Inc, Viridian Therapeutics, and Dianthus Therapeutics.
In a report released on May 11, Guggenheim also reiterated a Buy rating on the stock with a $30.00 price target.
Based on Amylyx Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $41.28 million. In comparison, last year the company had a GAAP net loss of $35.91 million
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMLX in relation to earlier this year. Most recently, in March 2026, James Frates, the CFO of AMLX sold 7,909.00 shares for a total of $114,838.68.
